Exact Sciences Corp. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2015; Reaffirms Revenue Guidance for the Year 2016
For the full year 2015, the company expects revenue to be approximately $39.0 million to $39.5 million, the result of completing approximately 104,000 Cologuard tests during its first full year of commercialization.
The company is reaffirming its guidance of completing more than 240,000 Cologuard tests and generating between $90 million-$100 million in revenue in 2016.